Vascular Endothelial Growth Factor (VEGF) Market Segmented By Human VEGF, Mouse VEGF, Rat VEGF, Rabbit VEGF Type with CHO, E. Coli, HEK, NSO, Insect Cells Expression Host
Industry: Healthcare
Published Date: June-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 440
Report ID: PMRREP33129
The global vascular endothelial growth factor (VEGF) market was valued at US$ 195.4 Mn at the end of 2021, with an estimated CAGR of 10.7% for the next ten years, which suggests a highly progressive market growth. A comprehensive industry study reveals that the market will surge to a valuation of US$ 590.6 Mn at the end of 2032.
According to Persistence Market Research, human VEGF held a market value of US$ 117.4 Mn in 2021, accounting for over 60% of the overall market share. Revenue from VEGF accounted for 17.2% share of the global growth factor market at the end of 2021.
| Attribute | Key Insights |
|---|---|
|
VEGF Market Size (2022) |
US$ 213.6 Mn |
|
Projected Market Value (2032) |
US$ 590.6 Mn |
|
Global Market Growth Rate (2022-2032) |
10.7% CAGR |
|
Market Share of Top 5 Countries |
64% |
The global VEGF market expanded at a CAGR of 6.8% over the last nine years (2012-2021).
Increasing incidence of renovascular disease (RVD) and coronary artery disease is leading to rising demand for an alternative treatment, which, in turn, is fuelling revenue growth of the global vascular endothelial growth factor market.
VEGF molecules have several applications and the development of new methods for disease interventions, as well as obtaining positive outlooks with the protein structure, have boosted research activities assessing the advantages of growth factors in disease development.
Renovascular disease (RVD) is a condition in which the kidneys gradually lose function, and existing treatments are ineffective. A conjugate of VEGF coupled with the elastin-like polypeptide (ELP) carrier protein and a kidney-targeting peptide at the N-terminus (KTP) is designed to investigate whether KTP-ELP VEGF treatment, which has a superior targeting profile, can effectively restore renal function.
Reduced renal vascular resistance (RVR), restored cortical perfusion, and reduction of vascular remodeling was linked to improvements in microvascular density after KTP-ELP VEGF treatment, thus enhancing the value of VEGF molecules in several clinical studies.
Investments in clinical trial investigations, as mentioned above, are anticipated to increase in the years ahead, which will bolster the growth of the market.
For regenerative angiogenesis, VEGF-A mRNA may propose a therapeutic utility. Intradermal VEGF-A mRNA was well tolerated in clinical trials, resulting in local functional expression of VEGF-A protein and transitory skin blood flow augmentation in individuals with type 2 diabetes. As a result, VEGF-A mRNA has the potential to be used as a regenerative treatment for ischemic cardiovascular disease and diabetes.
Thus, the global VEGF market is also expected to grow owing to an increase in research on the intradermal delivery of modified mRNA encoding VEGF-A, thus transforming the applicative approach of VEGF molecules from clinical interventions to a consumer-led market.
The global vascular endothelial growth factor market is expected to expand at a high CAGR of 10.7% and records sales worth US$ 590.6 Mn by the end of 2032.
“Use of VEGF for Treatment of Peripheral Vascular Diseases”
The angiogenic effects of VEGF and nerve growth factor gene co-delivery nanoparticles in cells and the hind limb ischemia mice model were evaluated recently (March 2022). The findings revealed increased HUVEC migration, tube formation, proliferation, and H2O2 damage resistance with VEGF and nerve growth factor gene co-delivery nanoparticles while simultaneously promoting VEGF and nerve growth factor co-expression.
VEGF and nerve growth factor gene co-delivery nanoparticles have also been found to improve blood perfusion, stimulate VEGF and nerve growth factor expression, and increase pericyte vascular coverage.
Overall, gene co-delivery nanoparticles containing VEGF and nerve growth factors have been found to reduce H2O2 levels while attaining gene co-delivery and promoting stable angiogenesis. As a result, promising treatment options for peripheral vascular disease are expected to propel the growth of the VEGF market over the forecast period.
Poly-l-lactide (PLA) loaded VEGF microparticles with a long-term release structure can be employed in proangiogenic therapy to reduce the negative effects of numerous administrations. VEGF can induce angiogenesis and signal vascular endothelial cells, which aid in cell proliferation and migration when given at the right dose.
The bioactivity of VEGF released from PLA particles was investigated using human umbilical vein endothelial cells (HUVEC) in proliferation and wound healing assays, and it was discovered that rVEGF is effective when combined with lactate (PLA), which could be useful for tissue remodeling, vasculogenesis, and angiogenesis.
Hence, the wide range of applications of VEGF will create lucrative opportunities for market players and is displaying a fast-growing trend in demand and sales.
“Short Half-life of VEGF Protein & Selection in Route of Administration for Drug Delivery”
Since its discovery and significance in the angiogenic process, VEGF has been viewed as a promising molecule for stimulating neovascularization in the infarcted heart. Even though multiple clinical trials were conducted, no therapeutic results were observed, attributable to VEGF's short half-life when injected directly into the tissue.
The short in-vivo half-life of VEGF limits intravenous administration, and the overall dose is limited by off-target site toxicity factors. The amount of VEGF localized in the ischemic zone following systemic treatment in the case of myocardial ischemia is low and does not last more than one day.
Drug delivery devices appear to be a promising option for overcoming the limitations in VEGF clinical trials in this context.
Moreover, the physical and chemical instability of integrating VEGF, or any protein, into an appropriate carrier presents distinct challenges. To avoid chemical instability, pressure, temperature, the presence of metal ions, pH, and denaturing agents such as surfactants must all be closely monitored during the manufacturing process.
This is a major challenge faced during the manufacturing of VEGF and may hinder market expansion.
How is the U.S. VEGF Market Progressing?
“Increase in Acquisitions by Manufacturers & Growing Focus on Better Treatment Options”
In 2021, the U.S. accounted for a market share of more than 94% in the North American vascular endothelial growth factor market, owing to manufacturers’ strategies to meet the unmet needs in the health sector in the country, thus contributing to market growth.
Furthermore, growing demand for recombinant proteins in the research sector and increasing government initiatives to encourage research-related activities will also contribute to the growth of the VEGF market in the U.S.
How is Demand for VEGF Shaping Up in Germany?
“Europe VEGF Market Led by Germany”
Germany accounted for 28.8% of Europe's vascular endothelial growth factor market share in 2021 and is projected to grow at a CAGR of 9.1%.
Germany holds the largest market share in Europe due to the presence of prominent players who are focused on the expansion of their manufacturing centers to provide products at affordable rates in the region, thus driving the growth of the German market.
Why is China Emerging as a Prominent Market for VEGF?
“High Investments in CMOs Driving Market Growth in China”
In 2021, the China vascular endothelial growth factor market was valued at US$ 9.5 Mn with a market share of 47.9% in East Asia.
Chinese leaders are making biologic contract manufacturing organizations (CMOs) a rational alternative to bio manufacturing companies, as they provide service to small- and medium-sized companies by investing in GMP facilities.
In addition, established companies tend to build more manufacturing facilities, thus contributing to market growth in China.
Which VEGF Type is Most Widely Used?
“High Demand for Human VEGF across Regions”
The human VEGF segment, among other VEGF types, accounts for the highest market share of more than 60% by revenue, followed by the mouse VEGF type with a growth rate of 10.4% in 2021.
Human VEGF induces the proliferation and migration of vascular endothelial cells and is essential for both, physiological and pathological angiogenesis, and thus, sees high demand.
Which Expression Hosts are in High Demand for Factor VEGF?
“E. coli Dominates Market among Other Expression Hosts”
E. coli, as an expression host, dominated the market with a revenue share of 40.2% in 2021, owing to the lack of glycosylation in the prokaryotic expression system.
Functional recombinant products using E. coli systems enable fast and cheaper production as compared to other available expression systems such as insect cell lines, mammalian cells, yeasts, and others, thereby allowing it to gain a higher market share value.
Which Application Accounts for Most VEGF Demand?
“Cell Culture-based Application Continues to Lead Market Share”
Cell culture held the highest market share of 25.9% in 2021 and is projected to dominate by expanding at 11.7% CAGR.
Many in-vivo studies have been conducted to explore the role of VEGF in tumor formation and progression. To study tumor cell responses under different pathological and physiological conditions, including cellular stresses, cell culture approaches have been promising in in-vitro models. Investigating VEGF expressions under cellular stresses is being explored through the application of cell cultures.
Leading VEGF providers are aiming at acquisitions and collaborations to expand their product portfolios and sales footprint across the globe.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2012-2021 |
|
Market Analysis |
US$ Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
VEGF Market by VEGF Type:
VEGF Market by Expression Host:
VEGF Market by Application:
VEGF Market by End User:
VEGF Market by Region:
To know more about delivery timeline for this report Contact Sales
The global vascular endothelial growth factor (VEGF) market was valued at US$ 195.4 Mn in 2021.
The VEGF industry is set to witness 10.7% CAGR and be valued at US$ 590.6 Mn by 2032.
The VEGF market expanded at 6.8% between 2012 and 2021.
Key players are Merck KGaA, Thermo Fisher Scientific Inc., Bio-Techne, GenScript, and Bio-Rad Laboratories, Inc.
VEGF for tissue repair processes, targeting VEGF with a bispecific fusion protein, raised VEGF in the diagnosis of POEMS Syndrome, and growing significance of genomics & proteomics are key market trends.
Human VEGF accounted for more than 60% market share in 2021.
The U.S., Germany, China, U.K., and France are leading countries in the VEGF space.
The U.S. accounted for more than 94% share of the North American market in 2021.
China held a share of 47.9% in East Asia, while India accounted for 45.6% of the South Asia market share, at the end of 2021.
